ArticleJournal of gastrointestinal oncology2026
An exploratory nomogram model with
Article in Journal of gastrointestinal oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: There are still difficulties in dividing patients into an microvascular invasion (MVI) high-risk and non-high-risk group among hepatocellular carcinoma (HCC) patients based on the pathology findings. This study investigated preoperative fluorine-18-fluorodeoxyglucose ( Methods: A retrospective analysis was conducted involving 79 HCC patients undergoing liver transplantation with preoperative Results: LASSO regression identified TMRmax and tumor diameter as significant factors that are associated with high-risk MVI. Multivariate analysis confirmed the independence of these two predictors: TMRmax [odds ratio (OR) =1.757, 95% confidence interval (CI): 1.124-2.746; P=0.01] and tumor diameter (OR =1.247, 95% CI: 1.067-1.456; P=0.005). ROC curve analysis indicated that a TMRmax ≥2.1 achieved a sensitivity of 70.27% and a specificity of 64.29% [area under the ROC curve (AUC) =0.716], while a tumor diameter ≥8.3 cm had a sensitivity of 51.35% and a specificity of 90.48% (AUC =0.729). The combined model demonstrated improved predictive performance (C-index =0.779, 95% CI: 0.672-0.865) with the nomogram demonstrating good calibration. Conclusions: TMRmax and tumor diameter may be closely associated with high-risk MVI in HCC. The exploratory model combining TMRmax and tumor diameter may help on preoperative risk stratification. Due to the small sample size from a single center, the results of this study warrant validation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.